These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22814006)

  • 1. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients.
    Tybura P; Samochowiec A; Beszlej A; Grzywacz A; Mak M; Frydecka D; Bieńkowski P; Mierzejewski P; Potemkowski A; Samochowiec J
    Pharmacol Rep; 2012; 64(3):528-35. PubMed ID: 22814006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.
    Tybura P; Trześniowska-Drukała B; Bienkowski P; Beszlej A; Frydecka D; Mierzejewski P; Samochowiec A; Grzywacz A; Samochowiec J
    Psychiatry Res; 2014 Oct; 219(2):261-7. PubMed ID: 24930580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The influence of antipsychotic therapy on the cognitive functions of schizophrenic patients].
    Tybura P; Mak M; Samochowiec A; Pełka-Wysiecka J; Grzywacz A; Grochans E; Zaremba-Pechmann L; Samochowiec J
    Psychiatr Pol; 2013; 47(4):567-78. PubMed ID: 24946464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
    Weiden PJ; Simpson GM; Potkin SG; O'Sullivan RL
    J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perazine and carbamazepine in comparison to olanzapine in schizophrenia.
    Ohlmeier MD; Jahn K; Wilhelm-Gossling C; Godecke-Koch T; Hoffmann J; Seifert J; Emrich HM; Schneider U
    Neuropsychobiology; 2007; 55(2):81-8. PubMed ID: 17570951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole versus other atypical antipsychotics for schizophrenia.
    Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
    Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review.
    Matza LS; Baker TM; Revicki DA
    CNS Drugs; 2005; 19(6):499-515. PubMed ID: 15963000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Associations between candidate genes with schizophrenia susceptibility and the treatment efficiency].
    Tybura P; Grzywacz A; Samochowiec A; Samochowiec J
    Psychiatr Pol; 2011; 45(6):811-23. PubMed ID: 22335125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms of the 5-HT2A receptor gene and clinical response to olanzapine in paranoid schizophrenia.
    Olajossy-Hilkesberger L; Godlewska B; Schosser-Haupt A; Olajossy M; Wojcierowski J; Landowski J; Marmurowska-Michałowska H; Kasper S
    Neuropsychobiology; 2011; 64(4):202-10. PubMed ID: 21912188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
    Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M
    J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.
    Lencz T; Robinson DG; Xu K; Ekholm J; Sevy S; Gunduz-Bruce H; Woerner MG; Kane JM; Goldman D; Malhotra AK
    Am J Psychiatry; 2006 Mar; 163(3):529-31. PubMed ID: 16513877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in chinese han schizophrenia patients.
    Yan P; Song M; Gao B; Wang S; Wang S; Li J; Fang H; Wang C; Shi J
    Psychiatry Res; 2020 Nov; 293():113470. PubMed ID: 32992097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
    N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New antipsychotics and schizophrenia: a review on efficacy and side effects.
    Serretti A; De Ronchi D; Lorenzi C; Berardi D
    Curr Med Chem; 2004 Feb; 11(3):343-58. PubMed ID: 14965236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.
    Shen YC; Chen SF; Chen CH; Lin CC; Chen SJ; Chen YJ; Luu SU
    J Psychiatr Res; 2009 Mar; 43(6):600-6. PubMed ID: 18926547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.